Takeda Pharmaceutical (NYSE:TAK) Posts Earnings Results, Beats Expectations By $0.54 EPS

Takeda Pharmaceutical (NYSE:TAK) announced its earnings results on Thursday, July 30th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.54, reports. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The firm had revenue of $7.50 billion for the quarter, compared to analysts’ expectations of $7.13 billion. Takeda Pharmaceutical updated its FY 2026 guidance to 3.009-3.009 EPS.

Here are the key takeaways from Takeda Pharmaceutical’s conference call:

• Q1 results were broadly on plan: Core revenue declined 0.5% and core operating profit fell 0.5% at constant exchange rates, while core EPS decreased 11.8% to JPY 154 due largely to an unfavorable comparison with the prior year’s tax benefit. Full-year guidance, including JPY 650–750 billion of free cash flow, was maintained.
• The company reported continued resilience in its established portfolio, with core inline brands growing 2.3% at constant exchange rates. ENTYVIO grew 4%, new launches increased 22.6%, and transformation savings are intended to fund investments in upcoming products and the late-stage pipeline.
• Takeda is preparing for a potentially significant launch cycle, with ORZEYFUL for narcolepsy type 1 and rusfertide for polycythemia vera expected to launch in the U.S. in the second half of 2026, followed by zasocitinib for psoriasis in the first half of 2027. ORZEYFUL has already received its first approval in China, while rusfertide has received FDA priority review.
• Zasocitinib produced encouraging phase III psoriasis results, demonstrating statistical superiority to deucravacitinib across primary and key secondary endpoints, with more than 35% of patients achieving complete skin clearance at week 16. Management also highlighted promising data in difficult-to-treat areas and additional development opportunities in inflammatory bowel disease and other immune-mediated conditions.
• Near-term financial performance remains pressured by mature-product erosion, including continued generic competition for Vyvanse, while operating cash flow was lower because of working-capital effects and free cash flow included a $200 million payment to Protagonist related to rusfertide rights. ENTYVIO biosimilar litigation is expected to take roughly three to five years, with U.S. entry timing still broadly anticipated around 2032.

Takeda Pharmaceutical Stock Performance

NYSE:TAK traded down $0.25 during trading hours on Friday, hitting $18.46. 1,499,536 shares of the company were exchanged, compared to its average volume of 3,088,415. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. Takeda Pharmaceutical has a 52-week low of $12.99 and a 52-week high of $18.90. The stock has a market capitalization of $59.15 billion, a price-to-earnings ratio of 54.29 and a beta of -0.07. The company’s 50 day moving average price is $17.26 and its 200-day moving average price is $17.20.

Insider Activity

In other Takeda Pharmaceutical news, insider Deidre Greenway sold 12,980 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $18.11, for a total transaction of $235,067.80. Following the sale, the insider owned 40,049 shares in the company, valued at approximately $725,287.39. The trade was a 24.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Giles Platford sold 31,083 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $531,519.30. Following the completion of the transaction, the insider owned 315,838 shares of the company’s stock, valued at approximately $5,400,829.80. The trade was a 8.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 592,922 shares of company stock valued at $10,340,896. 0.04% of the stock is owned by corporate insiders.

Institutional Trading of Takeda Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of the business. UBS Group AG grew its position in Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after purchasing an additional 1,869,323 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in Takeda Pharmaceutical by 132.1% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,828,778 shares of the company’s stock worth $41,413,000 after acquiring an additional 1,610,088 shares during the period. Qube Research & Technologies Ltd raised its position in Takeda Pharmaceutical by 407.9% during the third quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock valued at $25,998,000 after acquiring an additional 1,426,184 shares in the last quarter. Van ECK Associates Corp lifted its holdings in Takeda Pharmaceutical by 98.4% in the fourth quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock valued at $35,941,000 after acquiring an additional 1,143,117 shares during the period. Finally, Voloridge Investment Management LLC boosted its position in Takeda Pharmaceutical by 1,070.7% in the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock worth $15,005,000 after purchasing an additional 880,289 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TAK has been the topic of a number of research analyst reports. Zacks Research upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.